Adaptin Bio, Inc. (APTN): Total Assets
$619.2K
As of 2025-12-31
$981.5K
As of 2026-06-30
n/m
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $619.2K | +158.6% | 2026-04-01, Balance as of period end |
| 2024-12-31 | $239.4K | n/m | 2026-04-01, Balance as of period end |
| 2023-12-31 | $380 | -24.0% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $500 | n/a | 2024-04-01, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Adaptin Bio, Inc. (APTN) | 2025-12-31 | $619.2K | +158.6% |
| Liminatus Pharma, Inc. (LIMN) | 2025-12-31 | $512.8K | -90.5% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 2025-12-31 | $1.02M | -44.2% |
| Abpro Holdings, Inc. (ABPO) | 2025-12-31 | $1.06M | -77.2% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $1.53M | -7.1% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $1.64M | +195.7% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $3.18M | +1.2% |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $3.41M | -8.4% |
| Cero Therapeutics Holdings, Inc. (CERO) | 2025-12-31 | $3.64M | -41.3% |
Compare APTN, LIMN, BCLI, ABPO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗